Amgen reported 20% weight loss in its MariTide Phase II study results, but a 10% drop in share price suggests investors had ...
The Phase III trial of AXS-12 showed results over placebo as the company looks towards a new drug application for its ...
The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback